A 10%, suckling rat brain rabies vaccine free from encephalitogenic activity was prepared and inactivated with 1: 8,000 beta-propiolactone (BPL), or ultraviolet light, or a combination of ultraviolet light and BPL, or 1 % phenol. Potency was excellent in all samples, with the exception of the phenolized product which was marginal. A purified suckling rat brain (SRB) vaccine prepared by zonal centrifugation and inactivated with 1: 8,000 BPL contained about 0.01 the amount of protein nitrogen of the unpurified 10% SRB vaccine. This purified product passed the National Institutes of Health potency test for rabies vaccine after administration of a quantity equivalent to a standard 10% brain suspension.
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The classical rabies vaccines of neural tissue origin have generally been high-virus-titer antigens, but inoculation of humans with these vaccines has occasionally been complicated by both severe local reactions and various degrees of neuroparalytic involvement. More recently, the duck embryo vaccine has replaced brain tissue vaccines in the United States, practically eliminating postvaccinal reactions (10, 11) . However, the relatively high level of extraneous protein and lipid in this product leaves much to be desired.
In this era of cell culture vaccines, extensive efforts have been directed toward producing an ideal vaccine by using chicken, duck, hamster, pig, monkey, rabbit, mouse, dog, and human diploid cells (1, 5, 6, (14) (15) (16) . Adapting this highly neurotropic virus to a non-neural cell system has been fraught with problems of low virus titers, lack of a suitable serum substitute to obtain acceptable virus titers, and no really specific potency test for a cell culture product.
Recently, attempts have been made to eliminate the encephalitogenic activity associated with neural tissue vaccines (while preserving their high virus titers and excellent antigenicity) by using the brains of immature or suckling animals.
It has been known for some years that the degree of encephalitogenic activity of brain tissue is associated with the extent of myelin development and, therefore, with the ontogeny of the animal used as the vaccine source (7) .
In an extensive treatise on experimental allergic encephalitis (EAE), Lumsden et al. con- cluded that all encephalitogenic activity associated with mature brain tissue extracts may be narrowed to a common denominator, i.e., a dialyzable basic small polypeptide with a molecular weight of 4,400 to 4,800 (9).
Gispen et al., for example, have shown that 4-to 5-day-old rabbit brains are free from encephalitogenic activity when tested with Freund's adjuvant in guinea pigs (3, 4) . However, Svet-Moldavskij et al. were able to produce symptoms of EAE in guinea pigs with 2-day-old rabbit brain, and sheep brain had the encephalitogenic factor on the first day after birth (13). Fuenzalida et al. reported that mouse brain is free from EAE activity for at least 10 days after birth (2).
Sikes and Larghi were able to prepare a purified vaccine from suckling mouse brain by a combination of centrifugation and column chromatography (12) .
Svet-Moldavskij and his associates showed that the brains of albino rats did not become encephalitogenic until after the 18th day of life (13) . Because of their relatively long freedom from the encephalitogenic factor after birth and their size advantage over mice, the suckling rat brain was selected for further investigation. Encephalitogenic activity. The lots of SRB vaccine tested for encephalitogenic activity were prepared from rat brains harvested at a maximum of 12 days of age. Hartley guinea pigs were selected because of their high sensitivity to experimental allergic encephalitis (8) .
Symptoms of EAE were observed in guinea pigs inoculated with the vaccine made of 25'-adult rabbit brain suspension in Freund's adjuvant as early as 4 days postinoculation. The most consistent clinical observation in the animals was ascending bilateral paralysis with paralysis of the sphincter muscles. At no time during the 43-day observation period were clinical symptoms of EAE observed in guinea pigs inoculated with the 25-', suspension of SRB vaccine in Freund's adjuvant. A few guinea pigs died during the experiment from other causes (usually pneumonia). These animals were negative for EAE when the central nervous system (CNS) was examined for histopathological lesions.
The results listed in Table 2 indicate that a direct correlation existed between clinical symp- Purified SRB vaccine. The results of the purification of the SRB vaccines by zonal centrifugation are charted in Fig. I In the studies of Svet-Moldavskij et aLl. (13) , after over 12,000 human vaccinaLtions, not one case of postvaccinal encephalitis has been seen, and high-titered serum-neutrcllizing antibody has been observed regularly.
However, the vaccine has the disadvantages of high proteini nitrogen and phenol inactivation.
Also, some severe local reactions and a significant nuLmber of general reactions (headache, rise in body temperature, and nausea) have been seen in human subjects inoculated with this vaccine.
The purified SRB vaccine has the advantages of BPL inactivation and very low protein nitrogen (about 0.01 the amount of the conventional SRB vaccine). Furthermore, both lots of the purified product passed the NIH potency test when tested as equivalent to a standard 1(0' suspension of brain tissLIe (Table 3) .
LAV ENDFR PURIFIED RABIES VACCINE
It therefore appears that SRB vaccine can be improved by purification in the zonal centrifuge. A 100-ml sample of high-titered SRB vaccine (10-7. logs/0.03 ml) diluted with 1,600 ml of buffered sucrose during purification, and then still further diluted about 1:10 after purification, still yielded over 4 logs of virus/0.03 ml.
The isopycnic separation appears to be superior to the rate zonal method in that practically all of the high-titered virus (free from much extraneous protein, hemoglobin, and lipid) was collected in about 10 40-ml fractions.
This purified SRB vaccine, with good potency, has a lower protein nitrogen content than most cell culture rabies vaccines. 
